CLRB · Cellectar Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.01M | - | $2.52M | $2.39M | $3.43M | - | $5.49M | $7.35M | $7.38M | - |
| SG&A | $2.79M | - | $2.33M | $3.65M | $2.97M | - | $7.83M | $6.36M | $4.62M | - |
| Total Operating Expenses | $5.79M | - | $4.85M | $6.04M | $6.40M | - | $13.33M | $13.70M | $12.00M | - |
| D&A | - | - | - | - | $56.3K | - | - | - | $88.5K | - |
| Operating Income | ($5.79M) | - | ($4.85M) | ($6.04M) | ($6.40M) | - | ($13.33M) | ($13.70M) | ($12.00M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.65M) | - | ($4.44M) | ($5.45M) | ($6.60M) | - | ($14.66M) | ($919.4K) | ($21.58M) | - |
| EPS - Basic | ($1.33) | - | ($1.41) | ($3.39) | ($4.20) | - | ($11.10) | ($0.90) | ($22.20) | - |
| EPS - Diluted | ($1.33) | - | ($1.41) | ($3.39) | ($4.20) | - | ($12.00) | ($5.40) | ($22.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.35M | $13.20M | $12.55M | $11.04M | $13.91M | $23.29M | $34.26M | $25.87M | $40.03M | $9.56M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $1.44M | - | - | - | $4.11M | - | - | - | $5.62M |
| Current Assets | $9.27M | $14.04M | $13.62M | $12.62M | $14.89M | $24.25M | $35.90M | $27.91M | $41.37M | $10.45M |
| Total Assets | $11.12M | $14.98M | $14.63M | $13.70M | $16.04M | $25.47M | $37.29M | $29.38M | $42.91M | $12.08M |
| Current Liabilities | $4.87M | $4.75M | $4.91M | $5.87M | $6.02M | $9.39M | $20.31M | $15.17M | $16.27M | $12.94M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.40M | $5.06M | $5.25M | $6.23M | $6.41M | $9.80M | $20.75M | $15.62M | $16.74M | $13.43M |
| Stockholders' Equity | $3.34M | $8.54M | $8.00M | $6.09M | $8.25M | $14.29M | $15.16M | $12.38M | $26.17M | ($1.36M) |
| Retained Earnings | ($274.79M) | ($269.13M) | ($263.84M) | ($259.39M) | ($253.95M) | ($247.34M) | ($244.99M) | ($230.32M) | ($239.06M) | ($217.48M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.85M) | - | - | - | ($9.38M) | - | - | - | ($13.36M) | - |
| Investing Cash Flow | ($3.4K) | - | - | - | - | - | - | - | ($21.6K) | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | $43.85M | - |
| CapEx | $3.4K | - | - | - | - | - | - | - | $21.6K | - |
| Free Cash Flow | ($4.85M) | - | - | - | - | - | - | - | ($13.38M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.86 | - | - | - | - | - | - | - | 0.62 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -50.8% | - | -30.4% | -39.8% | -41.2% | - | -39.3% | -3.1% | -50.3% | - |
| Return on equity | -169.5% | - | -55.6% | -89.5% | -80.0% | - | -96.7% | -7.4% | -82.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.90 | 2.96 | 2.77 | 2.15 | 2.47 | 2.58 | 1.77 | 1.84 | 2.54 | 0.81 |
| Quick ratio | 1.90 | 2.96 | 2.77 | 2.15 | 2.47 | 2.58 | 1.77 | 1.84 | 2.54 | 0.81 |
| Cash ratio | 1.71 | 2.78 | 2.56 | 1.88 | 2.31 | 2.48 | 1.69 | 1.71 | 2.46 | 0.74 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.33 | 1.75 | 1.83 | 2.25 | 1.94 | 1.78 | 2.46 | 2.37 | 1.64 | -8.90 |
| Liabilities / Assets | 0.58 | 0.34 | 0.36 | 0.45 | 0.40 | 0.38 | 0.56 | 0.53 | 0.39 | 1.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.2x | - | 2.2x | 1.9x | 53.6x | - | 168.5x | 226.8x | 133.9x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 9.5% | - | 63.6% | 55.9% | 46.7% | - | -41.6% | -65.2% | -37.9% | - |
| Net income growth (YoY) | 14.4% | - | 69.7% | -492.6% | 69.4% | - | -6.8% | 88.8% | - | - |
| EPS growth (YoY) | 68.3% | - | 88.3% | 37.2% | 81.1% | - | -891.7% | -639.7% | -2821.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -59.6% | -40.3% | -47.3% | -50.9% | -68.5% | - | - | - | 256.8% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cellectar Biosciences against the 5 most active filers in the same SIC group.